Enoblituzumab

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators[1].

Product Specifications

CAS Number

[1353485-38-7]

Product Name Alternative

MGA271

UNSPSC

12352203

Target

CD276/B7-H3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/enoblituzumab.html

Purity

99.16

Solubility

H2O

Smiles

[Enoblituzumab]

Molecular Weight

(146.1 kDa)

References & Citations

[1]Hińcza-Nowak K, et al. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. Genes (Basel) . 2021 Sep 28;12 (10) :1534. |[2]Chapoval, et al. Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. Russ J Bioorg Chem 45, 321–334 (2019) . |[3]Loo D, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012 Jul 15;18 (14) :3834-45.